Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
4D pharma plc LBPS
$1.65
На 18:04, 12 мая 2023
Ключевые показатели
-
Marketcap
0.00000000
-
week52high
10.38
-
week52low
1.50
-
Revenue
718000
-
P/E TTM
-1
-
Beta
3.26641100
-
EPS
0.00000000
-
Last Dividend
0.00000000
-
Next Earnings Date
31 мар 2022 г. в 04:00
Описание компании
4D pharma plc, together with its subsidiaries, develops live biotherapeutic products (LBPs) in the United Kingdom. The company develops therapeutic candidates, including MRx0518 for the treatment of cancer and immune-oncology diseases; MRx-4DP0004 for the treatment of asthma; MRx0029 and MRx0005 the treatment of central nervous system disorders; Blautix for irritable bowel syndrome; and Thetanix for pediatric crohn's disease. It also develops products candidates, such as MRx1299 for solid tumors, MRx0006 for rheumatoid arthritis, and MRx0002 for multiple sclerosis. In addition, the company develops MicroRx platform to discover new LBP candidates for major diseases. 4D pharma plc has a collaboration agreement with Merck KGaA, Darmstadt, Germany and Pfizer to evaluate MRx0518; strategic collaboration agreement with University of Texas MD Anderson for discovery and development of LBPs in oncology; and Merck & Co., Inc. to conduct a clinical trial evaluating the combination of Keytruda, MRx0518 in patients with solid tumors, and to discover and develop LBPs for vaccines. The company was formerly known as Schosween 18 Limited. 4D pharma plc was incorporated in 2014 and is headquartered in Leeds, the United Kingdom.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Chardan Capital | Neutral | Buy | 27 июн 2022 г. |
| Ladenburg Thalmann | Buy | 13 мая 2021 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
4D pharma says phase II IBS results published in scientific journal
Proactive Investors
16 ноя 2022 г. в 02:47
4D pharma PLC said results from a phase II evaluation of its key irritable bowel treatment LBP Blautix have appeared in a peer-reviewed scientific publication. The article in Alimentary Pharmacology & Therapeutics took a deeper dive into the already revealed finding that the drug has an impact on the symptoms of the two separate IBS cohorts – those with constipation and those with diarrhoea.
4D Pharma outlines phase II plans for promising cancer drug candidate
Proactive Investors
27 мая 2022 г. в 02:50
4D pharma PLC (AIM:DDDD, NASDAQ:LBPS) will deliver what's called a ‘trial in progress' poster at a world-leading cancer conference outlining the plans and aims of a phase II study of its cancer drug candidate used alongside an immune checkpoint inhibitor drug. Delegates at the American Society of Clinical Oncology meeting in Chicago will be told that MRx0518 will be coupled with Bavencio to treat a common form of bladder cancer.
4D pharma conference poster underlines safety and potential efficacy of asthma drug candidate
Proactive Investors
17 мая 2022 г. в 02:29
4D pharma PLC (AIM:DDDD, NASDAQ:LBPS) said it will present an update from the phase I/II trial of its putative asthma treatment at an industry conference. The data will be delivered as a late-breaking abstract, which will underline the safety and efficacy of MRx-4DP0004.
4D Pharma has a busy year ahead after a successful 12 months of clinical research
Proactive Investors
01 апр 2022 г. в 03:29
4D pharma PLC (AIM:DDDD, NASDAQ:LBPS) has some significant milestones upcoming this year after a successful 12 months of developing assets that target the human microbiome, the bacterial ecosystem in the gut. The update was provided alongside prelims which showed the drug developer posted a £26.1mln operating loss in the year to 31 December 2021 after it spent £19.8mln on research and development.
4D Pharma PLC soars after meeting endpoint early
Proactive Investors
23 мар 2022 г. в 12:02
4D pharma PLC (AIM:DDDD, NASDAQ:LBPS) jumped 27% in London trading after the company hit its primary efficacy target in a phase I/II trail of one of its lead assets in kidney cancer. Chief Executive Officer Duncan Peyton described the progress as potentially “really meaningful” for patients and their families, in a conference call on Wednesday.